Related Experiment Video
Updated: Jun 22, 2026

09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
Omega-3 fatty acids and dementia
Greg M Cole1, Qiu-Lan Ma, Sally A Frautschy
1Department of Medicine at University of California, Los Angeles, CA, USA. gmcole@ucla.edu
Prostaglandins, Leukotrienes, and Essential Fatty Acids
|June 16, 2009
Summary
Omega-3 fatty acids, particularly docosahexaenoic acid (DHA), show promise in protecting against cognitive decline and Alzheimer
Area of Science:
- Neuroscience
- Nutritional Science
- Epidemiology
Background:
- Epidemiological studies consistently link reduced omega-3 fatty acid intake or levels with an increased risk of age-related cognitive decline and dementia, including Alzheimer's disease (AD).
- Docosahexaenoic acid (DHA), an omega-3 fatty acid, appears protective against AD and other dementias in numerous studies, though the ApoE4 genotype may limit its protective effects.
- DHA exerts broad neuroprotection through various mechanisms, including neuroprotective metabolites, reduced arachidonic acid metabolites, and enhanced trophic factors, while also mitigating dementia risk factors like head trauma, diabetes, and cardiovascular disease.
Purpose of the Study:
- To investigate the neuroprotective mechanisms of docosahexaenoic acid (DHA) against Alzheimer's disease (AD) pathology.
- To evaluate the potential of DHA for the prevention or treatment of age-related cognitive decline and AD.
- To synthesize epidemiological and basic research data to inform clinical trial recommendations for DHA interventions.
Main Methods:
- Review and synthesis of epidemiological data associating omega-3 fatty acid intake with cognitive decline and dementia risk.
- Analysis of basic research data detailing the neuroprotective mechanisms of DHA at the cellular and molecular level.
- Examination of existing clinical trial data and expert panel recommendations regarding DHA for AD prevention and treatment.
Main Results:
- DHA specifically protects against AD by limiting amyloid-beta (Abeta) peptide production and accumulation.
- DHA suppresses Abeta-induced signaling pathways, including those that phosphorylate tau protein and promote neurofibrillary tangle pathology.
- Current clinical trial results suggest DHA may be more effective when initiated early or combined with antioxidants.
Conclusions:
- Docosahexaenoic acid (DHA) possesses multiple mechanisms of neuroprotection relevant to Alzheimer's disease (AD) and age-related cognitive decline.
- Expert panels recommend clinical trials investigating DHA for AD prevention and treatment, emphasizing early intervention and combination therapies.
- Further clinical research is warranted to confirm the efficacy of DHA in preventing and treating AD, particularly in specific patient populations.
Related Concept Videos
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...